Home › Research › Topics › monoclonal
monoclonal
332 studies tagged monoclonal, dated 2000 to 2026-09-09. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
Studies
332 studies carry this tag.
Date range
2000 to 2026
Top journals
- Alzheimer's & dementia : the journal of the Alzheimer's Association 26
- Journal of Alzheimer's disease : JAD 21
- The journal of prevention of Alzheimer's disease 20
- Alzheimer's research & therapy 18
- Alzheimer's & dementia (New York, N. Y.) 14
148 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
The results of the aducanumab studies have not been published in peer-reviewed form and both the analysis presented by Dr Knopman and collaborators and this perspective are based on data presented in 2019 at the Clinical Trials in AD (CTAD) meeting3; both discussions must be seen as tentative until full data are available.
-
43/100
Acute symptoms included headache and encephalopathy, and magnetic resonance imaging revealed ARIA-E and ARIA-H. Malignant hypertension and epileptiform activity were treated with nicardipine and levetiracetam.
-
The amyloid cascade hypothesis, according to which the self-assembly of amyloid-β peptide (Aβ) is a causative process in Alzheimer's disease, has driven many therapeutic efforts for the past 20 years.
-
We identified 53 clinical trials involving 58 FDA-approved agents.
-
The 2020 pipeline has innovations in clinical trials and treatment targets that provide hope for greater success in AD drug development programs.
-
Alzheimer's Disease (AD) therapeutics based on the amyloid hypothesis have repeatedly failed in clinical trials.
-
41/100
Development of disease-modifying treatments for Alzheimer's disease (AD) has been challenging, with no drugs approved to date.
-
Although more than 100 years have passed since Alois Alzheimer reported a case of Alzheimer's disease (AD), a definitive answer to the causes of cognitive impairment in the disease remains elusive.
-
Crenezumab doses of ≤120 mg/kg intravenously q4w were well tolerated.
-
The termination of many clinical trials of amyloid-targeting therapies for the treatment of Alzheimer's disease (AD) has had a major impact on the AD clinical research enterprise.
-
PET amyloid levels were consistent with sparse-to-no neuritic amyloid-β plaques in 51% of patients after 2 years of therapy.
-
Disease-modifying therapies for proteinopathies are urgently needed yet clinical trials for the major neurodegenerative diseases, Alzheimer's and Parkinson's, have been failing at an alarming rate leaving patients and caregivers scrambling for any sign of hope.
-
Drug development continues robustly at all phases despite setbacks in several programs in the recent past.
-
In terms of efficacy, the review showed a statistically, but not clinically significant, improvement in favor of immunotherapy versus placebo.
-
Based on the improved efficacy/safety profile in non-clinical models of SAR228810, a first-in-man single and multiple dose administration clinical study has been initiated in AD patients.
-
Solanezumab produced statistically significant increases in CSF total Aβ isoforms versus placebo, which correlated with CSF solanezumab concentration.
-
Conventional parallel group randomized controlled clinical trials (RCT) in Alzheimer’s disease (AD) are too large, long, expensive and insensitive to clinical change to meet the urgent need for an effective treatment.
-
41/100
Aducanumab, a human-derived antibody targeting amyloid-β (Aβ), is in Phase 3 clinical trials for the treatment of Alzheimer's disease.
-
In patients treated up to 36 months, amyloid plaque levels continued to decrease in a dose- and time-dependent manner, with levels in the 10 mg/kg fixed-dose group reaching and remaining below a quantitative cut-point discriminating a positive/negative scan. 1 Reduced amyloid plaque levels were also observed in patients switched from placebo to aducanumab during the LTE.
-
41/100
Overall, ARIA-E was mild and asymptomatic.
-
Infusion of bapineuzumab 0.5 or 1.0 mg/kg every 13 weeks for up to 3 years was generally well tolerated, with a safety and tolerability profile similar to that in previous studies.
-
No significant difference was seen in cognitive and functional decline between early and delayed treatment groups.
-
To review the optimality and safety of different anti-Amyloid- β (Aβ) immunotherapies for Alzheimer's disease (AD).
-
The recent failure of several clinical trials on anti-β-amyloid (Aβ) drugs in Alzheimer's disease (AD) suggested earlier intervention in the disease course.
-
The majority of putative disease-modifying treatments in development for Alzheimer's disease are directed against the amyloid-β (Aβ) peptide.
-
39/100
The Dominantly Inherited Alzheimer's Network (DIAN) observational study compared pathophysiological markers between mutation carriers and non-carriers in autosomal dominant Alzheimer's disease.
-
Efforts to develop new therapies to combat Alzheimer's disease suffer from extraordinarily high failure rates that make it difficult to justify continued investment in the field.
-
No beneficial effects were observed in the dual primary outcome measures for the 2 IVIg doses tested.
-
ARIA was detected more often on MRI scans when every scan was reviewed by trained neuroradiologists and results adjudicated.
-
The amyloid hypothesis has been the dominant framework for Alzheimer's disease (AD) research, including the development of anti-AD therapies.
-
Immunotherapeutics targeting amyloid-β (Aβ) have had mixed results in clinical trials.
-
Calcium homeostasis plays a major role in maintaining neuronal function under physiological conditions.
-
There are currently 24 agents in 36 trials in phase III of AD drug development.
-
Crenezumab is a humanized anti-amyloid-beta (Aβ) monoclonal IgG4 antibody in development for the treatment of Alzheimer’s disease (AD).
-
In this single-dose study, aducanumab demonstrated an acceptable safety and tolerability profile and linear PK at doses ≤30 mg/kg (clinicaltrials.govNCT01397539).
-
During the last few decades, relevant efforts have been reported to design nanocarriers for drug transport through the blood brain barrier (BBB).
-
BAN2401 was well-tolerated across all doses.
-
N/A. ENGAGE and EMERGE are Phase 3 clinical trials designed to confirm the clinical efficacy and safety profile of aducanumab in individuals with Early AD.
-
Asymptomatic ARIA-E was detected in solanezumab-treated and placebo-treated AD patients.
-
At the 8th International Conference on Clinical Trials in Alzheimer's Disease held November 5-7, 2015 in Barcelona, Spain, promising data were presented on two candidate Alzheimer's disease immunotherapeutic agents, gantenerumab and aducanumab.
-
Based on integrated review of laboratory, electrocardiogram, adverse events, and MRI, AAB-003 was safe and well tolerated up to 8 mg/kg for up to 91 weeks (FIH and extension trials) in patients with mild to moderate AD.
-
The DIAN observational study compared the pathophysiological markers between mutation carriers and non-carriers for autosomal dominant Alzheimer's disease.
-
Primary biomarker efficacy endpoints were not statistically significant in either dose group.
-
Amyloid-related imaging abnormalities (ARIA) represent the major severe side effect of amyloid-beta (Aβ) immunotherapy for Alzheimer's disease (AD).
-
These findings describe solanezumab effects on efficacy/safety measures in a mild AD population.
-
SCarlet RoAD (NCT01224106; WN25203), a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-year study of gantenerumab in prodromal AD, was the first global registration-enabling study using biomarker screening for entry and a single clinical endpoint for outcome.
-
Aducanumab (BIIB037) is a human monoclonal antibody selective for aggregated forms of beta-amyloid peptide being investigated as a disease-modifying treatment for AD.
-
Adjunctive florbetapir-PET increased quality-adjusted life years (QALYs) by 0.008 years and increased costs by 36 compared to SCE alone (incremental cost-effectiveness ratio [ICER], 4,769).
-
The CAD106 first-in-human study demonstrated a favorable safety profile and promising antibody response.
-
Trials missing primary efficacy end points raise the question of whether the choice of drug or the limitations of disease biology were at fault.
From across this tag
7 of the 332 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 7. The same 7 appear here every time.
- Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease
- Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
- Anti-amyloid antibody therapies in Alzheimer's disease
- Towards pharmacological prevention of Alzheimer disease
- Donanemab: Not two without a third
- Alzheimer's disease: treatments in discovery and development
- Lecanemab appropriate use recommendations for clinical practice in the UK